Tocilizumab for COVID-19: A systematic review and meta-analysis of randomized controlled trials
The effective treatment modalities for severe coronavirus disease 2019 (COVID-19) are needed. As the primary cause of mortality is a hyperinflammatory state, the interleukin-6 antagonist tocilizumab has been used in multiple clinical studies. We conducted this systematic review and meta-analysis to...
সংরক্ষণ করুন:
| প্রধান লেখক: | , , , , , |
|---|---|
| বিন্যাস: | Artigo |
| ভাষা: | Inglês |
| প্রকাশিত: |
PAGEPress Publications
2022-02-01
|
| মালা: | Monaldi Archives for Chest Disease |
| বিষয়গুলি: | |
| অনলাইন ব্যবহার করুন: | https://www.monaldi-archives.org/index.php/macd/article/view/2136 |
| ট্যাগগুলো: |
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!
|